Abstract Body

Testosterone therapy (TTh) use is highly prevalent among middle-aged and older men with HIV (MWH) in the United States, but its cardiovascular safety is unclear. We assessed progression of subclinical coronary artery disease by TTh use status among MWH in the Multicenter AIDS Cohort Study (MACS).

MWH in the MACS CVD sub-study in 4 U.S. cities from 2010-17 were included, each of whom underwent two coronary CT angiography (CCTA) measurements 4.5±0.7 years apart. Inclusion criteria were age 40-70 without coronary intervention or kidney dysfunction. TTh use was self-reported semi-annually, and classified as never, prior to baseline CCTA (former), after baseline CCTA (new), or both (consistent). We evaluated associations between TTh and progression of subclinical atherosclerosis, specifically 1)coronary artery calcium (CAC), 2)total plaque volume, and 3)noncalcified plaque volume. CAC progression was defined by incident CAC if baseline CAC=0, ≥10 Agatston unit/yr increase if baseline CAC=1-100, and ≥10%/yr increase if baseline CAC>100, and analyzed by robust Poisson regression. Progression was defined by the upper tertile of annualized change in total and noncalcified plaque volume, using multinomial logistic regression. Regression models adjusted for demographic, cardiovascular risk, and HIV-related clinical factors, and baseline serum testosterone.

Median age among the 300 MWH was 51 years, 48% were white, 41% were in the ASCVD high risk category, 91% were on antiretroviral therapy, and 81% had undetectable HIV viral load (<20 copies/mL). TTh trajectories were: 70% never, 8% former, 7% new, and 15% consistent use. Median total testosterone was 606 ng/dL (IQR=445,808). Adjusting for age, race, testosterone<300 ng/dL, and cardiovascular and HIV cofactors, the risk of significant CAC progression was 2.0 times greater among continuous users (p=0.03) and 2.4 times greater among new users (p=0.01) relative to former users. We observed a similar trend for total and noncalcified plaque volume progression, but these estimates were not statistically significant (Table).

MWH who continued or started TTh were twice as likely as former users to experience significant CAC progression over 4 years. To our knowledge, this is the first contemporary study of cardiovascular outcomes associated with TTh use among MWH; additional observational data should be leveraged to further elucidate the potential health implications of TTh use among MWH.